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ABSTRACT 
OBJECTIVE: The increasing incidence of adrenal incidentalomas is attributed to the widespread 
use of imaging techniques. Although in most cases adrenal incidentalomas are benign and non-
functioning, their clinical relevance is related to the possibility of malignancy or hormonal 
production. Their follow-up approach is controversial since their natural history is unknown. Our 
aim is to characterize patients with adrenal incidentalomas from a single tertiary-care centre in 
Portugal (Centro Hospitalar do Porto). 
DESIGN AND METHODS: This observational, retrospective and longitudinal study included all 
patients with adrenal incidentaloma observed at an outpatient clinic specialized in adrenal gland 
disease between January 2014 and March 2018. Adrenal incidentaloma was defined as an 
adrenal mass detected on imaging not performed for suspected adrenal disease. Parameters 
regarding demographic features and imaging, clinical and analytical evaluations were collected. 
RESULTS: A total of 142 patients were included with a mean age at diagnosis of 59.4 years; 
54.9% were women. Most subjects (61.3%) had non-functioning adrenal incidentalomas; 29.2% 
possible autonomous cortisol secretion, 5.7% autonomous cortisol secretion, 2.8% primary 
hyperaldosteronism and 0.9% pheochromocytoma. A non-contrast attenuation coefficient >10 
Hounsfield units was found in at least one mass in 8.7% patients and a maximum diameter ≥40 mm in 6.4%. Median follow-up duration was 2.0 years. An increase in the number of 
masses was observed in 21.1% patients and a decrease in 7.8%; an increase in maximum 
diameter >5 mm was observed in 23.3% patients and a decrease in 4.4%. Neither primary nor 
metastatic adrenal cancer were found. Moreover, 54.4% patients developed comorbidities; 
median time from diagnosis to their development was 4.0 years. Additionally, five cardiovascular 
events were registered; median time from diagnosis to these events was 2.0 years. Regarding 
cortisol production, during follow-up, 11.6% patients showed a worsening and 23.3% an 
improvement. No patients developed primary hyperaldosteronism, pheochromocytoma or overt 
endocrine disease. 
CONCLUSIONS: Our results suggest that in most cases adrenal incidentalomas remain stable 
throughout imaging follow-up and that malignant transformation is rare. The risk of developing 
comorbidities appears to be high, however prevention may improve these patients’ outcomes 
since few cardiovascular events were observed. Concerning hormonal follow-up, cortisol 
production may vary over time, contrarily to other adrenal hormones. 
KEYWORDS: Adrenal incidentaloma; Obesity; Diabetes Mellitus; Dyslipidaemias; Hypertension; 
Atherosclerosis.  
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RESUMO 
OBJETIVOS: O aumento da incidência de incidentalomas da suprarrenal é atribuído ao uso 
crescente das técnicas de imagem como meios complementares de diagnóstico. Apesar de, na 
maioria dos casos, estes incidentalomas serem benignos e não funcionantes, a sua relevância 
clínica deve-se principalmente à possibilidade de malignidade ou produção hormonal. O 
protocolo de seguimento é controverso já que a sua história natural não está esclarecida. O 
objetivo deste trabalho é caracterizar os doentes com incidentaloma da suprarrenal de um 
hospital terciário terciários em Portugal (Centro Hospitalar do Porto). 
DESENHO E METODOLOGIA: Estudo observacional, retrospetivo e longitudinal que incluiu 
todos os doentes com incidentaloma da suprarrenal observados na consulta externa específica 
para doença da suprarrenal entre Janeiro de 2014 e Março de 2018. Foi definido como 
incidentaloma da suprarrenal uma massa detetada por estudos imagiológicos não realizados 
por suspeita de doença da suprarrenal. Foram registados parâmetros relativos a características 
demográficas e às avaliações imagiológica, clínica e analítica. 
RESULTADOS: Foram incluídos 142 doentes com uma idade média ao diagnóstico de 59,4 
anos; 54,9% eram mulheres. A maioria dos doentes (61,3%) apresentava incidentaloma não-
funcionante, 29,2% possível secreção autónoma de cortisol, 5,7% secreção autónoma de 
cortisol, 2,8% hiperaldosteronismo primário e 0,9% feocromocitoma. Verificou-se uma 
densidade >10 unidades de Hounsfield em pelo menos uma massa em 8,7% dos doentes e um 
diâmetro máximo ≥40 mm em 6,4%. A duração mediana do seguimento foi de 2,0 anos. 
Observou-se um aumento do número de massas em 21,1% dos doentes e uma diminuição em 
7,8%; um aumento do diâmetro máximo >5 mm em 23,3% dos doentes e uma diminuição em 
4,4%. Nenhum doente apresentava ao diagnóstico ou desenvolveu durante o seguimento 
cancro da suprarrenal primário ou metastático. Adicionalmente, 54,4% dos doentes 
desenvolveram comorbilidades; o tempo mediano entre o diagnóstico e o seu aparecimento foi 
de 4,0 anos. Registaram-se cinco eventos cardiovasculares e o tempo mediano entre o 
diagnóstico e estes eventos foi de 2,0 anos. Relativamente à produção de cortisol, durante o 
seguimento, 11,6% dos doentes revelaram um agravamento e 23,3% uma melhoria. Nenhum 
doente desenvolveu hiperaldosteronismo primário, feocromocitoma ou doença endócrina 
clínica. 
CONCLUSÕES: Os nossos resultados sugerem que a maioria dos doentes com incidentaloma 
da suprarrenal permanece imagiologicamente estável durante o seguimento e que a 
transformação maligna é rara. O risco de desenvolvimento de comorbilidades parece ser 
elevado, mas a prevenção poderá melhorar os resultados, já que a incidência de eventos 
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cardiovasculares foi baixa. A produção de cortisol poderá variar ao longo do tempo, o que não 
se verifica com as restantes hormonas produzidas pela suprarrenal. 
PALAVRAS-CHAVE: Incidentaloma da suprarrenal; Obesidade; Diabetes Mellitus; Dislipidemia; 
Hipertensão; Aterosclerose. 
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INTRODUCTION 
Adrenal incidentalomas (AIs) are adrenal masses detected in imaging studies not 
performed for suspected adrenal disease.1 In recent years, AIs have become progressively 
relevant in clinical practice as their incidence and prevalence considerably increased. This is 
believed to be the result of both population-ageing as well as technological advances which 
resulted in a widespread use of imaging techniques.2-6 Based on imaging and autopsy studies, 
it is estimated that the prevalence of AIs is 1-10%, increasing with age, with a peak of incidence 
in the fifth to seventh decades of life.5, 6 Although its prevalence is superior in women in imaging 
series, in autopsy ones no sex difference was found.5, 6 
AIs form a heterogeneous group that comprises a wide range of entities, simultaneously 
including functioning and non-functioning (i.e. hormone producing or not), benign and 
malignant, and adrenal and extra-adrenal aetiologies.1 Although the majority of cases are non-
functioning benign incidentalomas (most often adenomas), the clinical relevance of AIs is 
related to the possibility of malignancy or hormone production (most often cortisol).1, 6, 7 
Subclinical Cushing’s syndrome or, according to the latest European Society of 
Endocrinology guideline, autonomous cortisol secretion (ACS) is defined by the presence of 
biochemical evidence of an increased cortisol production without the classical clinical features 
of hypercortisolism that define overt Cushing’s syndrome (OCS).1, 8 Analogously to OCS, ACS 
has been associated with an increased risk of osteoporosis and fragility fractures, and several 
metabolic abnormalities such as insulin resistance, type 2 diabetes mellitus (DM), obesity and 
hypertension, all of which are associated with an increased risk of cardiovascular events and 
mortality.1, 9-21 However, ACS is much more prevalent than OCS. It is estimated that ACS is 
present in 1.0-29.0% of AIs and, thereby, its prevalence in adult population is between 0.2-
2.0%.1, 22, 23 The high prevalence of ACS combined with the associated risk of comorbidities and 
mortality justify its relevance. Interestingly, recent studies have also linked non-functioning AIs 
with a higher risk of comorbidities and cardiovascular events, raising the hypothesis that these 
two categories are different phases of the same process and not distinct entities.24-26 
The European Society of Endocrinology guideline published in 2016 on the management 
of AIs has received some criticism regarding the recommendations on follow-up of patients with 
non-functioning benign lesions and with possible autonomous cortisol secretion (PACS) 
without comorbidities.27, 28 These recommendations are markedly different from those of the 
previous guideline by the American Association of Clinical Endocrinologists and the American 
Association of Endocrine Surgeons of 2009, however the quality of the evidence supporting 
them is classified as very low.1, 27, 28 In addition, European Society of Endocrinology guideline 
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itself proposes two studies about biochemical and radiological follow-up which further confirms 
how insufficient data about these themes there is and validates this criticism. The first one is a 
long-term study with annual biochemical work-up of patients with AI to clarify if such a long-
term hormonal assessment is justified and determine the true incidence of relevant diseases. 
The second is a large, long-term study to define whether or not ACS is associated with increased 
mortality and other hard clinical endpoints.1 In fact, more evidence is needed to define the ideal 
follow-up strategy that must weigh the risk of complications related to radiation exposure from 
repeated computed tomography scans (CTs), the psychological impact and the economic costs 
against the benefits to patients.29 
The aims of our study are (1) to evaluate imaging, clinical and analytical (biochemical 
and hormonal) features at diagnosis and throughout follow-up in patients with AI from a single 
tertiary-care centre in Portugal and (2) compare patients with non-functioning AI with those with 
PACS or ACS regarding these features. 
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SUBJECTS AND METHODS 
STUDY DESIGN AND SUBJECTS 
This observational longitudinal study was carried out at Hospital de Santo António – 
Centro Hospitalar do Porto (HSA–CHP) – a tertiary-care and university centre. The records 
regarding all consecutive patients observed at an outpatient clinic specialized in adrenal gland 
disease between January 2014 and March 2018 were retrospectively analysed. All adult patients 
with AI were included. Patients whose diagnosis was made by imaging studies done for (1) 
symptoms or signs related to adrenal hormone excess or deficiency, (2) investigation of 
hypertension, (3) screening in the context of hereditary syndromes causing adrenal tumours, (4) 
evaluation of extra-adrenal malignancies (diagnosis, staging or follow-up) or (5) an otherwise 
suspected adrenal disease were excluded. Patients who did not meet the criteria of having a CT 
and a clinical, a biochemical and a hormonal evaluation were also excluded. 
Parameters regarding demographic features and imaging, clinical, biochemical and 
hormonal evaluations were collected. The first office visit’s date and the specialty of the physician 
who referred the patient were also registered. All data was obtained by perusal of clinical records 
(paper and/or computer) as well as CT and laboratory reports. 
The periodicity and parameters included in these patients’ evaluation was guided by 
different protocols based on the current guidelines at the time. Regarding imaging evaluation, 
this protocol defines that all AIs diagnosed by ultrasonography (US) or magnetic resonance scan 
(MR) are evaluated by CT up to 6 months after the first office visit. Moreover, patients diagnosed 
by CT but without a report or with an incomplete report and that we do not have access to the 
diagnostic exam for re-evaluation by the study’s radiologist (R.M.) also repeat CT up to 6 months 
after the first office visit. Follow-up protocol included a CT performed 1, 3 and 5 years after the 
first office visit until 2017, when the European Society of Endocrinology guidelines were adopted.1 
Since then, the study’s radiologist analyses all first CTs and those patients whose CT is 
unequivocally benign do not repeat it unless any clinical or analytical abnormality that requires 
further imaging is identified throughout follow-up. Regarding clinical and analytical evaluation, 
our institution’s protocol includes two initial evaluations during the first 6 months after the first 
office visit, followed by an annual evaluation unless any abnormality that requires further 
investigation is identified in the initial screening or throughout follow-up. 
  
SUBJECTS AND METHODS 
 4 
IMAGING EVALUATION 
The AI diagnosis’ date, the diagnostic imaging modality and the reason for performing 
this exam were recorded. Registered imaging characteristics included the number of masses; 
their localization (right or left adrenal gland or bilateral); their diameter, defined as its maximum 
transverse diameter; and their density, defined as non or pre-contrast attenuation coefficient 
and categorized as ≤ or >10 Hounsfield units (HU). When non or pre-contrast attenuation 
coefficient was >10 HU, absolute and relative washouts after contrast were also recorded. 
All these imaging characteristics were obtained from CTs which were not always 
performed by the same equipment nor evaluated by the same radiologist. In case of doubt 
regarding the report or incomplete reports, the images were re-evaluated by the study’s 
radiologist. 
CLINICAL EVALUATION 
According to our protocol, in each office visit, symptoms and signs of adrenal hormone 
excess or deficiency, prescribed medication, smoking habits, cardiovascular events, height (only 
on the first visit), body weight, waist circumference and systolic and diastolic blood pressure are 
registered. 
Demographic data included age and sex. Clinical data included all the registered 
parameters previously referred as well as deceases and their causes. Former smoker was defined 
as having ceased smoking at least 6 months before the assessment. Cardiovascular events 
encompassed myocardial infarction, transient ischemic attack, stroke and acute ischemia in the 
context of peripheral artery disease. 
ANALYTICAL EVALUATION 
Following our protocol, the first evaluation is done within 3 months after the first office 
visit. Blood samples are obtained between 8-9 h a.m., after an 8-h overnight fasting. Saliva 
samples are collected between 11-12 h p.m. (late night) and 7-8 h a.m. (morning). 24-h urine 
samples are collected according to standard recommendations. All patients receive detailed 
instructions on how to properly perform saliva sampling and urine collection at home. This first 
evaluation includes general biochemical parameters as creatinine, urea, sodium, potassium, 
chloride, alanine aminotransferase, aspartate aminotransferase, fasting glucose, haemoglobin 
A1c – only in patients with DM – total cholesterol, low-density lipoprotein cholesterol (c-LDL), 
high-density lipoprotein cholesterol (c-HDL) and triglycerides. It also includes a hormonal 
evaluation with (1) morning and late night salivary cortisol (MSC and LNSC, respectively) and 
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24-h urinary free cortisol (UFC) to evaluate cortisol secretion; (2) plasma metanephrines and 
24-h urinary fractionated catecholamines and metanephrines to exclude pheochromocytoma; 
and (3) plasma aldosterone and direct renin concentrations to exclude primary 
hyperaldosteronism (PHA). Since 2017, these two last parameters are only evaluated in patients 
with hypertension or unexplained hypokalaemia1. 
The second evaluation occurs within 3 months after the second office visit. It includes 
an overnight low-dose dexamethasone suppression test (1 mg DST): 1 mg of dexamethasone 
(Decadron®) is administrated between 11-12 h p.m. on the day before and blood samples for 
cortisol measurement are obtained in the following morning between 8-9 h a.m. 
In the ensuing annual evaluations, blood, saliva and urine samples are collected 
following the same protocol. These evaluations included the general biochemical and hormonal 
parameters previously referred. Since 2017, only general biochemical parameters are evaluated, 
unless any hormonal or clinical abnormality that needs further investigation is identified1. 
All biochemical and hormonal studies were performed at HSA–CHP laboratory. 
Creatinine, urea, glucose, total cholesterol, c-HDL and triglycerides were measured by standard 
procedures, with intra and inter-assay coefficients of variation <2.8% and <3.9%, respectively. 
Sodium, potassium and chloride were measured by indirect potentiometry, with intra and inter-
assay coefficients of variation <0.7% and <1.5%, respectively. All these parameters were 
measured using an automated autoanalyzer (Cobas 8000, Roche Diagnostics, Mannheim, 
Germany). Friedewald formula was used to calculate c-LDL. 
Saliva samples were collected using cotton swabs from Salivette® tubes (Sarstedt, 
Nümbrecht, Germany). Salivary and serum cortisol were measured using an automated 
electrochemiluminescence immunoassay (Cobas e601, Roche Diagnostics, Mannheim, 
Germany). Cross-reactivity with dexamethasone was negligible and intra and inter-assay 
coefficients of variation were 9.3 and 14.2%, respectively. UFC was measured using a 
chemiluminescent microparticle immunoassay (ARCHITECT i2000SR, Abbott), with intra and 
inter-assay coefficients of variation of 5.3 and 6.2%, respectively. Plasma metanephrines were 
measured with a chromatography-tandem mass spectrometry assay, with intra and inter-assay 
coefficients of variation of 6.6 and 8.3%, respectively. Urinary fractionated catecholamines and 
metanephrines were measured with a high-performance liquid chromatography method with 
electrochemical detection, with intra and inter-assay coefficients of variation of 2.9 and 4.1% for 
catecholamines and 2.7 and 4.4% for metanephrines, respectively. Aldosterone and renin were 
measured with a radioimmunoassay (CISBIO, Codolet, France), with intra and inter-assay 
coefficients of variation of 8.3 and 8.4% for aldosterone and 3.6 and 5.0% for renin, respectively. 
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DIAGNOSTIC CRITERIA 
An AI was defined as an adrenal mass detected on imaging not performed for suspected 
adrenal disease.1 
OCS, ACS, PACS, pheochromocytoma and PHA were diagnosed based on the European 
Society of Endocrinology Clinical Practice Guidelines and our institution’s protocols. 
OCS diagnostic criteria were (1) presence of clinical features of hypercortisolism and (2) 
at least two of the following: LNSC >0.35 μg/dL in two measurements, UFC above the upper 
limit of the normal range for the assay (176 μg/24h) in two measurements and serum cortisol 
>1.8 μg/dL after 1 mg DST.8 ACS was defined as serum cortisol >5.0 μg/dL after 1 mg DST and 
lack of clinical features of hypercortisolism and PACS was defined as serum cortisol >1.8 and ≤5.0 μg/dL after 1 mg DST and lack of clinical features of hypercortisolism.1 
Pheochromocytoma diagnostic criteria were (1) plasma metanephrines or 24-h urinary 
fractionated catecholamines or metanephrines ≥3 folds the upper limit of the normal range for 
the assay and/or (2) diagnostic histopathologic characteristics after surgical resection.30 
Regarding PHA, plasma aldosterone (pg/mL) and direct renin (pg/mL) concentrations 
measured at the same time were used to calculate plasma aldosterone/renin ratio and a ratio 
>57 was considered a positive screening. This ratio was a screening test and if positive it was 
repeated after minimizing confounding factors (for instance, medications). Saline infusion test 
was performed to confirm diagnosis.31  
Hypertension was defined as systolic blood pressure ≥140 mmHg and/or diastolic 
blood pressure ≥90mmHg on at least two blood pressure measurements per visit and on at 
least two visits32 and/or prescription of any antihypertensive medication. 
Dyslipidaemia was defined as c-LDL ≥115 mg/dL and/or c-HDL ≤40 mg/dL in men or ≤45 mg/dL in women and/or triglycerides ≥150 mg/dL33 and/or prescription of any  
antidyslipidaemic medication. 
DM was defined as plasma glucose ≥126mg/dL in at least two measurements34 and/or 
prescription of any antidiabetic medication. Prediabetes was defined as a plasma glucose ≥100 
and <126 mg/dL.34 Insulin resistance was estimated using (1) the homeostasis model 
assessment, calculated according to the equation 1;35 and using (2) the triglyceride/glucose 
index, calculated according to the equation 2.36 
insulin (μIU/ml) x plasma glucose (mg/dL)
405
                                                                (Equation 1) 
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ln ( triglycerides (mg/dL) x plasma glucose (mg/dL)
2
)                                             (Equation 2) 
Obesity was defined as a body mass index (BMI) ≥30 kg/m2 and being overweight as 
BMI ≥25 and <30 kg/m2.7 Waist circumference was considered abnormal if ≥94 cm in men 
and ≥80 cm in women.33  
SURGERY CRITERIA 
A diameter ≥40 mm, functioning AIs (PHA, pheochromocytoma and OCS) or features 
suggesting malignancy on CT (irregular margins, non- or pre-contrast attenuation coefficient 
>10 HU, absolute washout ≤60% and relative washout ≤40% both after contrast, among 
others1) were indications for surgical treatment. 
STATISTICAL ANALYSIS 
Regarding analysis of imaging features, when a patient had more than one mass, 
diameter was defined by the mass with the greatest diameter and density was considered ≤10 
HU if all masses had a density ≤10 HU and >10 HU if one of the masses had a density >10 HU. 
Follow-up analysis only included patients with a follow-up duration ≥1 year. 
Statistical analysis was performed using IBM SPSS Statistics, version 25.0. Regarding 
descriptive statistics, continuous variables were reported as mean (standard deviation (SD)) or 
median (interquartile range (IQR)), depending on whether distribution was considered normal 
or not, respectively, by Shapiro-Wilk test. For categorical variables, descriptive statistics were 
reported as absolute frequency (relative frequency, %). Continuous variables were analysed 
using parametric (t-test or one-way ANOVA) or non-parametric (Mann-Whitney U, Kruskal-
Wallis H and Wilcoxon tests) tests when appropriate. Categorical variables were analysed using 
Chi-square test or Fisher’s exact test when appropriate. Statistical significance was defined as a 
probability value (P) <0.05. 
ETHICS STATEMENT 
This study was approved by the ethical committee of CHP in the 21st of February 2018 
and was conducted in agreement with the principles of the Declaration of Helsinki. Informed 
consent was obtained for all patients. 
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RESULTS 
From January 2014 to April 2018, 245 patients were observed at our outpatient clinic. 
After analysing their records, we identified 173 patients with AI. Within these, only 142 had a CT 
and a clinical, a biochemical and a hormonal evaluation and, thereby, were enrolled in our study 
(Figure 1). 
Among patients enrolled, 54.9% were women. Mean age at diagnosis was 59.4 years; 
and 75.4% patients were between the fifth to seventh decades of life (Table I). 
In total, 90 patients had a follow-up duration ≥1 year, with a median duration of 2.0 
(IQR 1.0-5.0) years. Throughout follow-up, 24 patients were lost: 1 died in the context of 
decompensated heart failure; 2 underwent unilateral adrenalectomy; and 21 discontinued follow-
up (6 decided by the physician and 15 on their own account). 
IMAGING EVALUATION 
In 79.6% patients, AIs were diagnosed by CT or MR (111 by CT and 2 by MR); in the 
remaining cases AIs were diagnosed by US. The most frequent reason for diagnostic imaging 
was gastrointestinal symptoms or disease (50.0% patients). 
The majority of patients (83.1%) had unilateral masses, 53.4% of which on the left 
adrenal gland. Left sided masses were more likely to be identified by CT or MR than by US (51.3% 
vs. 17.2%; P=0.004) (Table II). No differences were found between patients with left, right or 
bilateral masses in regard to sex, age and BMI. 
Most patients (79.6%) had a single adrenal mass; 14.8% had two adrenal masses. No 
significant differences were found between patients with different numbers of masses in regard 
to age, sex, BMI and diagnostic method. The number of masses identified by CTs performed 
during follow-up was compared with the number of masses at first CT: 19 (21.1%) patients had 
an increase; and 7 (7.8%) a decrease, in 3 of which the only mass disappeared. Median time 
from diagnosis to the increase or decrease in the number of masses was 2.3 (IQR 1.4-3.9) and 
4.6 (IQR 2.4-5.1) years, respectively. No differences were found between patients whose number 
of masses increased, decreased or did not change concerning age, sex, BMI, diameter and 
density at diagnosis. 
Mean diameter was 21.9 mm. Diameter was significantly higher in bilateral masses than 
in left ones (27.5 (SD 14.4) vs. 20.4 (SD 12.7) mm; P=0.026) and in patients with two or more 
masses than in those with only one (26.3 (SD 13.3) vs. 20.7 (SD 11.4) mm; P=0.012). It was also 
significantly higher in AIs diagnosed by US than in those diagnosed by CT or MR (25.7 vs. 20.9 
RESULTS 
 9 
mm; P=0.019). Concerning diameter, no differences were found in regard to sex and no 
correlations were found concerning age or BMI. In 2.8% subjects, diameter was <10 mm, all 
diagnosed by CT; in 6.4%, diameter was ≥40 mm.  
All diameters measured in CTs performed during follow-up were compared with the 
diameter measured in first CT: 21 (23.3%) patients had an increase >5 mm, seven of which >10 
mm; and 4 (4.4%) had a decrease >5 mm, one of which >10 mm. Median time from diagnosis 
to the detection of this increase or decrease was 2.4 (IQR 1.6-4.7) and 1.5 (IQR 1.2-2.9) years, 
respectively. No association was found between a change in diameter >5 mm and a change in 
number of masses. There were also no differences between patients whose diameter increased 
>5 mm, decreased >5 mm or did not change >5 mm concerning age, sex, BMI, diameter and 
density at diagnosis. Moreover, an increase of diameter to a value ≥40 mm was observed in 3 
(3.3%) patients; none of them had a density >10 HU and their mean diameter at diagnosis was 
33 (7.2) mm. 
In 18.4% patients no density was reported by the radiologist and we did not have access 
to the images. Among the remaining patients, 8.7% had a density >10 HU. One of these patients 
did not perform a contrast enhanced CT since he had a suspicion of pheochromocytoma. The 
remaining nine had an absolute washout >60% and a relative washout >40%. No significant 
differences were established between patients whose density at diagnosis was >10 HU and those 
whose density was ≤10 HU in regard to age, sex or diameter. 
An imaging worsening (defined as a change in density from ≤10 HU to >10 HU) was 
detected in 8 (8.9%) patients. Median time from diagnosis to worsening was 2.0 (IQR 1.3-3.9) 
years. All these patients revealed an absolute washout >60% and a relative washout >40% in 
contrast enhanced CTs. No relation was found between worsening and a change in diameter >5 
mm or number of masses. There were also no differences between patients with or without an 
imaging worsening concerning age, sex and diameter at diagnosis. 
Finally, neither primary nor metastatic adrenal cancer was found in our study at 
diagnosis or during follow-up. 
CLINICAL AND BIOCHEMICAL EVALUATIONS  
Median time from diagnosis to the first visit at our outpatient clinic was 5.0 (IQR 3.0-
10.0) months; this time was >12 months in 33 (23.2%) patients. In total, 43.7% patients were 
referred by family physicians (Figure 2). 
At diagnosis, 69.6% patients had a BMI ≥25 kg/m2 (41.3% of which had obesity); 66.2% 
dyslipidaemia; 56.3% hypertension; 34.5% tobacco smoking habits; 33.1% glucose intolerance 
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(70.2% of which had DM); and 9.9% history of cardiovascular events (Table III). Only 59 patients 
had a waist circumference measurement, the majority (n=56, 94.9%) presented a waist 
circumference ≥94 or 80, depending on sex. Within these, 14 (25.0%) had a BMI <25 kg/m2, 23 
(41.1%) were overweight and 19 (33.9%) obese. 
Throughout follow-up, 54.4% patients developed comorbidities, 22.4% of which 
developed two comorbidities. Prediabetes (28 new cases), hypertension (16) and dyslipidaemia 
(14) were the most frequent (Figure 3). Median time from diagnosis to the development of these 
comorbidities was 5.0 (IQR 2.0-10.0) years. Among patients who developed comorbidities, 39 
(79.6%) already had comorbidities at diagnosis. Patients who did not have comorbidities at 
diagnosis had a significantly higher proportion of comorbidities’ development (83.3% vs. 50.0%; 
P=0.031). BMI was significantly lower in patients who developed comorbidities (26.7 (SD 4.4) 
vs. 29.3 (SD 4.9) kg/m2; p=0.039). No differences were found between patients who developed 
comorbidities throughout follow-up and those who did not regarding age, sex, first 1 mg DST, 
change in cortisol production, diameter at diagnosis and change in number of masses or in 
diameter >5mm. In total, five cardiovascular events were registered and median time from 
diagnosis to these events was 2.0 (IQR 1.5-5.0) years. 
Clinical and biochemical features at diagnosis and 5 years after the diagnosis are shown 
in Table IV. When patients with available data from both periods were selected, we found an 
increase of 6.3 mg/dL in fasting glucose (n=34; P=0.029) and a decrease of 5.5 mg/dL in c-HDL 
(n=17; P=0.044). No significant differences were found regarding the other features.  
HORMONAL EVALUATION  
Overall, 106 patients performed a complete initial hormonal evaluation (i.e. the two 
evaluations within 6 months after the first office visit). Most patients (61.3%) had non-
functioning AIs, 29.2% PACS, 5.7% ACS, 2.8% PHA and 0.9% pheochromocytoma (Figure 4). 
Two patients with PHA and the one with pheochromocytoma simultaneously presented an 
abnormal cortisol production: the former had PACS and ACS and the latter had PACS. 
Hypertension was present at diagnosis in all patients with PHA and absent in the one 
with pheochromocytoma. Further, no patients with PHA revealed hypokalaemia (potassium <3.5 
mmol/L) at diagnosis.  
During follow-up, only 43 patients performed another complete hormonal evaluation. 
Regarding cortisol production, a worsening was observed in 11.6% patients, nevertheless no 
patients developed OCS. Conversely, 23.3% patients showed an improvement. Moreover, 7.0% 
patients presented an oscillating profile and the remaining 58.1% persisted stable. No 
differences were found between patients whose cortisol production worsened, improved, 
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oscillated and did not change throughout follow-up regarding age, sex, BMI, first 1 mg DST, 
diameter at diagnosis and change in the number of masses or in diameter >5 mm. Regarding 
the production of other hormones, no changes were registered: no patients developed 
pheochromocytoma or PHA. These changes resulted in a final distribution of 48.8% non-
functioning AIs, 37.2% PACS, 9.3% ACS and 4.7% PHA. 
Hormonal parameters at diagnosis and 5 years after the diagnosis are shown in Table 
IV. When patients with available data from both periods were selected, no significant differences 
were found between diagnosis and 5 years after diagnosis regarding these parameters. 
SURGERY 
A total of 16 (11.3%) patients had indication for surgery, 13 at diagnosis and three during 
follow-up: nine had a diameter ≥40 mm; three PHA; and one pheochromocytoma and a density 
>10 HU (Figure 1).  
Only three patients underwent surgery (unilateral adrenalectomy): the one with 
pheochromocytoma at diagnosis and the others during follow-up (both with a diameter ≥40 
mm, one with PACS and the other with a non-functioning AI). The pheochromocytoma 
diagnosis was confirmed by histopathology; the others histopathology was cortical hyperplasia 
and adenoma, respectively. None of these patients experienced corticotroph insufficiency after 
surgery. 
The remaining ten patients who did not undergo surgery either are waiting for surgery, 
had bilateral masses, refused surgery, were lost to follow-up (transferred to other institutions) 
or reduced mass diameter to <40 mm.  
NON-FUNCTIONING VERSUS POSSIBLE OR AUTONOMOUS CORTISOL SECRETION 
Regarding demographic features, patients with PACS or ACS were older than those with 
non-functioning either at diagnosis or 5 years after (63.4 vs. 57.2 years; P=0.006 and 68.3 years 
vs. 60.2 years; P=0.006, respectively) (Table V). No differences between patients with PACS or 
ACS and those with non-functioning were found in regard to sex, comorbidities and clinical and 
biochemical features either at diagnosis or 5 years after. Moreover, no differences were found 
regarding imaging features – location, number of masses, diameter and density at diagnosis 
(Table VI) and change in number of masses or in diameter >5 mm throughout follow-up. 
Among the 90 patients included for follow-up analysis, 77 patients performed a complete 
initial hormonal evaluation (Figure 3). Within these, excluding the 2 patients with PHA, 64.0% 
were non-functioning and the remaining PACS or ACS. Throughout follow-up, comparing non-
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functioning vs. PACS or ACS, 60.4% vs. 48.1% patients developed comorbidities (P=0.304). 
Within these patients, 20.7% vs. 38.5% developed two comorbidities (P=0.270). Prediabetes (15 
vs. 9 new cases), hypertension (10 vs. 4) and dyslipidaemia (9 vs. 4) were the most frequent. 
Median time from diagnosis to development of these comorbidities was 5.5 (IQR 1.0-10.0) vs. 
4.0 (IQR 2.0-10.0) years (P=0.868). Among patients who developed comorbidities, 11 (84.6%) 
vs. 22 (75.9%) had at least one comorbidity at diagnosis (P=0.695). Moreover, 4 (11.8%) patients 
with PACS or ACS had a cardiovascular event vs. 1 (1.9%) patients with non-functioning. Median 
time from diagnosis to these events was 2.0 (IQR 1.3-2.8) years for patients with PACS or ACS. 
The only event in patients with non-functioning occurred 7.0 years after diagnosis.  
Since the role of MSC, LNSC, UFC and inversion of the circadian rhythm (evaluated with 
MSC and LNSC) in the diagnostic approach of AI is not as well established as it is for OCS, we 
performed a subanalysis to compare patients with PACS or ACS with those with non-functioning 
AI regarding these variables and evaluate their agreement with 1 mg DST. We verified that 
although LNSC at diagnosis was significantly lower in patients with non-functioning vs. those 
with PACS or ACS (0.118 vs. 0.446; P=0.005), there were no significant differences concerning 
MSC and UFC. When analysing the agreement between 1 mg DST and LNSC at diagnosis, we 
obtained a Kappa coefficient of 0.3 when using 1.8 μg/dL as cut-off for 1 mg DST and of 0.2 
when using 5.0 μg/dL. It was not possible to analyse the agreement between 1 mg DST and UFC 
at diagnosis since there were no values of UFC above the upper limit of normal range (176 μg/24h).  
Among the 93 patients who had at least 1 evaluation of MSC and LNSC at diagnosis, 14 
patients had inversion of the circadian rhythm on the first evaluation. No significant differences 
were established between patients with PACS or ACS and those with non-functioning AIs 
regarding inversion of the circadian rhythm (8 (25.0%) patients vs. 6 (9.8%); P=0.069).
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DISCUSSION  
In our series, there were slightly more women (54.9%) than men. Regarding sex 
distribution evidence is conflicting: some studies are in agreement with ours and described a 
tendency to a higher prevalence in women (55.2-73.2%);6, 19, 37-46 others in men (52.7-61.0%);47-49 
and others, including autopsy series, reported no differences.6, 50-53 This higher prevalence in 
women is generally attributed to a referral bias since it is believed that abdominal diagnostic 
procedures are performed more frequently in women.6 
Mean age at diagnosis (59.4 years) was consistent with the literature (52-69 years).6, 19, 
37-45, 47-49, 52-55 Additionally, the majority of patients were in the fifth to seventh decades of life, that 
corresponds to AI’s incidence peak.6 This distribution may be either a consequence of a higher 
number of diagnostic procedures in older patients (requested by routine or disease) or a result 
of development of adrenal masses with age.38 The latter is in agreement with autopsy series38, 50, 
51 and its mechanism may involve ischemia followed by compensatory hyperplasia.38, 52, 56, 57 
IMAGING EVALUATION 
The majority of AIs were diagnosed by CT, followed by US and MR. This distribution is 
in agreement with some studies, conducted in 3 different countries (Croatia, Japan and Sweden) 
and published between 2002 and 2016;40, 42, 44, 49 but not with a widely cited study conducted in 
Italy and published in 2000, which refers US as the most frequent diagnostic technique.38 Since 
the majority of studies after 2000 excluded cases diagnosed by US and/or MR,41, 47, 48, 58 evidence 
is unclear. Nevertheless, the difference between these studies could be explained by a more 
widespread use of CT and MR nowadays and by geographic differences that may be associated 
with different accessibilities to imaging modalities. 
Globally, reasons for diagnostic imaging in our study were similar to those described in 
literature.38, 40, 42, 47, 49, 52, 55, 59 Gastrointestinal symptoms or disease was the most frequent cause 
followed by genitourinary symptoms or disease. This is supported by several studies that 
described general check-up (when this category was considered) and gastrointestinal or 
genitourinary symptoms (particularly, abdominal pain and haematuria) as the most frequent 
reasons for abdominal imaging in the setting of AI’s diagnosis.38, 40, 42, 47, 49, 52, 55, 59 
In our series, the majority of patients (83.1%) had unilateral masses, which is consistent 
recent studies (75.2-92.5%).19, 38-42, 45-47, 49, 52, 53, 55, 58-60 Unilateral masses were slightly more 
frequent on the left gland (53.4%) than on the right. Evidence regarding this side distribution is 
conflicting: some recent studies are in agreement with ours and described unilateral masses’ 
tendency to be more frequently located on the left gland (60.5-67.3%);39, 41, 47, 49, 58 others (mostly 
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older) on the right (55.9-72.9%);6, 19, 38, 46, 61, 62 and others, including CT and autopsy series, 
reported no differences.6, 37, 54 
Moreover, left sided masses were more likely to be identified by CT or MR than by US. 
Our results are in agreement with others that showed US detected right-sided masses more 
often than left-sided ones38, 49 and that CT detected them at similar rates.38 This difference is due 
to the fact that US is able to visualize the right adrenal gland better than the left, being less 
efficient than CT and MR in detecting masses on the left side.6, 16, 38, 58, 63, 64 This fact could also 
elucidate why in older studies masses were more frequently located on the right adrenal gland, 
since US was generally the most frequent diagnostic method.47  
Additionally, diameter was significantly higher in bilateral masses than in left ones; this 
is in agreement with Li et al. who found that bilateral masses were larger but not with Vassilatou 
et al. who found no differences.52, 60 No differences were found between patients with right, left 
and bilateral masses concerning sex, age and BMI. Regarding age and BMI, this is in agreement 
with previous studies; considering sex, Li et al. found that bilateral masses were more frequent 
in men, but the other studies found no differences.40, 52, 59, 60 
In our study, most patients (79.6%) had a single mass, in a proportion similar to that 
described by Cho et al. (88.7%).47 As far as we know, there are no studies that analysed the 
change in the number of masses throughout follow-up. In our study, the proportion of patients 
that presented this change was low (28.9%) and an increase in the number of masses was more 
frequent than a decrease (21.1 vs. 7.8%). Interestingly, in 3.3% patients the only mass 
disappeared. No parameter that distinguished patients concerning change in number of masses 
was identified. 
Mean diameter obtained in our study (21.9 mm) is similar to that described by some 
recent studies (17.2-25.0 mm).19, 39, 40, 42, 45, 47-49, 52, 53, 58 However, it is lower than that described in 
older studies (30-35 mm).6 This may be due to the multiple AI definitions (that may or may not 
include masses <10 mm, for instance), a different distribution of diagnostic modalities (as 
discussed previously, it appears that CT is replacing US as the most frequent modality, 
increasing the sensibility of the diagnosis) and to an improved resolution of imaging methods, 
particularly CT an MR.39 Furthermore, no differences were found in mean diameter in regard to 
sex, age or BMI, which is in agreement with Kastelan et al.40 
Additionally, the proportion of cases with a diameter <10 mm (2.8%) and ≥40 mm 
(6.4%) is in agreement with other studies (1.7-6.2% and 7.0-8.6%, respectively).19, 39, 41, 47, 49 The 
fact that all masses with a diameter <10 mm were detected by CT is also in agreement with 
Tabuchi et al. who observed that the majority of masses measuring <10 mm were diagnosed by 
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CT.49 Moreover, but contrarily to Tabuchi et al., diameter was significantly higher in masses 
identified by US.49 These last two findings reflect the greater resolution and sensibility of CT.  
Results concerning change in diameter during follow-up in our study were similar to 
those from other studies with a follow-up duration between 1.6-3.0 years: 72.3% of patients in 
our study vs. 78.2% in other studies presented no change in diameter; 23.3% vs. 2.7-16.3% 
increased (7.8% vs. 0-0.6% >10 mm); and 4.4% vs. 1.7-6.9% decreased.19, 40, 42, 47 In our study 
the proportion of patients with an increase in diameter was slightly higher. This may be due to 
the fact that CTs were neither analysed by the same radiologist (which is associated with a certain 
inter-observer variability) nor always performed in the same equipment. Similarly to our study, 
in other studies, age, sex, BMI, diameter and density at diagnosis were not parameters that 
distinguished patients concerning change in diameter.19, 47 Moreover, we found an increase to ≥40 mm in a higher proportion of patients (2.1% vs. 0%).40 These differences may be also due 
to the methodological aspects already mentioned. 
The proportion of patients with no density reported by the radiologist (18.4%) was higher 
than that observed in other studies (2.8-7.0%).40, 53 Therefore, the importance of increasing the 
referring physicians as well as radiologists awareness about the significance of a complete and 
detailed report or images access during the patient’s management becomes evident, as to 
assure there is no unnecessary radiation exposure. The proportion of patients with a density >10 
HU (8.7%) was lower than that described by other studies (24.0%-56.6%).40, 41 The absence of 
a significant difference between these patients and those with a density ≤10 HU in regard to 
diameter is not supported by Kastelan et al. that described that the first group of patients had a 
larger diameter.40  
In our knowledge, there are no studies that analysed the change in density throughout 
follow-up. As with number of masses and diameter, our study revealed a low proportion of 
patients with worsening of these imaging features throughout follow-up. 
Finally, the fact that neither primary nor metastatic adrenal cancer were found at 
diagnosis in our study is compatible with one study,49 but not with others, that describe 
malignancy in 0.4-29.0% of patients.6, 38-42, 47, 48, 52, 54 This variability between studies may be due 
to differences in sample size and inclusion criteria, namely including or not patients with history 
of extra-adrenal cancer. In our study patients whose diagnosis was made by imaging studies 
performed during evaluation of extra-adrenal malignancies were excluded. Furthermore, the 
absence of malignant transformation is compatible with recent studies.19, 29, 40, 45, 48 
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CLINICAL AND BIOCHEMICAL EVALUATION 
Almost half of our patients (43.7%) were referred to our clinic by a primary care 
physician. These results call attention to the necessity of educating these physicians regarding 
the importance of promptly referring these patients to an endocrinologist. Time from diagnosis 
to the first visit to our outpatient clinic was >12 months in 23.2% patients, which once more 
illustrates the importance of bringing to attention an early referral. In our knowledge, there are 
no studies that evaluated time between diagnosis and first Endocrinology clinical evaluation nor 
the medical specialties of the physicians who referred the patients. 
The proportion of patients with different comorbidities at diagnosis in our study is in 
agreement with those described in literature: 69.6% of patients in our study vs. 26.5-54.0% in 
other studies had an abnormal BMI (23.2% vs. 26.5-28.6% obesity); 66.2% vs. 14.2-48.9% 
dyslipidaemia; 56.3% vs. 38.3-69.3% hypertension; 33.1% vs. 15.0-37.3% glucose intolerance 
(23.2% vs. 13.3-19.9% DM); and 9.9% vs. 8.7-26.5% history of cardiovascular events.19, 40, 42, 45, 47, 
49, 52 Although our study reveals a tendency to slightly higher proportions of these comorbidities, 
there is great variability between studies that could be attributed to differences regarding 
inclusion criteria, referral pattern and even diagnostic criteria. 
Few patients had a waist circumference measurement at diagnosis, thus our results 
should be interpreted with caution. Nevertheless, it is important to highlight that 25% of patients 
had an abnormal waist circumference, despite having a normal BMI. This, allied to the fact that 
waist circumference is an important cardiovascular risk modifier, emphasizes the importance of 
measuring it in all patients. 
During follow-up, 54.4% patients developed comorbidities but only five cardiovascular 
events occurred. Moreover, regarding clinical and biochemical characteristics, no differences 
were found when comparing data at diagnosis and 5 years after the diagnosis except for plasma 
glucose and c-HDL which worsened. Although this worsening was statistically significant, it was 
not clinically significant and could be explained by the ageing of the sample. 
This high prevalence and incidence of comorbidities should be interpreted keeping in 
mind the mean age of our sample and that age is an important risk factor for all these 
comorbidities or events. Since we did not have a control group, they could not be attributed to 
AI and advanced age by itself could explain the high prevalence and incidence of comorbidities 
registered. Additionally, all these patients were being submitted to primary, secondary and even 
tertiary prevention measures which may interfere in the natural history of these diseases by 
improving its course or even delaying its beginning. This may explain the low incidence of 
cardiovascular events.  
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HORMONAL EVALUATION 
In our study, the majority of patients had non-functioning AIs (61.3%), which is 
compatible with what is described in the literature (68.0-88.6% of patients).1, 6, 19, 38-41, 47-49, 52, 54 
PACS or ACS was the most common functioning AI in our sample, which, along with the 
distribution of functioning AIs, is also consistent with what is described in the literature: 34.9% 
of patients in our study vs. 1.0-29.0% in other studies had PACS or ACS; 2.8% vs. 0.4-11.5% had 
PHA; and 0.9% vs. 0.9-14.0% had pheochromocytoma.1, 6, 19, 38-41, 47-49, 52, 54 The prevalence of 
PACS or ACS is highly variable between studies and this can be attributed to the different 
diagnostic tests and criteria used. In fact, there is no gold standard for the diagnosis and authors 
may use only one test or a combination of tests (generally, 1 mg DST is used as screening test 
and if positive may be complemented by other tests). Additionally, the cut-off values vary, for 
instance 1.8 and 5.0 µg/dL in 1 mg DST are used. Coexistence of PACS or ACS with PHA has 
also been observed in Tabuchi et al. and in a similar proportion (1.4 vs. 1.3%).49 
Within patients with PHA, the proportion of patients with hypokalaemia at diagnosis in 
our study was lower than that described Hong et al. (0 vs. 37.1%).48 
The change in cortisol production in our study is compatible with recent studies with a 
follow-up duration between 1.9-7.5 years: a worsening was observed in 11.6% of patients in our 
study vs. 0-12.9% in other studies and an improvement in 23.3% vs. 0-28.0%.19, 40, 45, 47, 48, 65 In 
our knowledge, no study reported an oscillating pattern of cortisol production. Once more, this 
variability between studies may be attributed to different diagnostic criteria. Moreover, the non-
existence of dexamethasone dosing restricts the interpretation of 1 mg DST results.  
Notwithstanding the limitations of 1 mg DST, cortisol production appeared to variate 
during follow-up, which supports the contemporary view that cortisol production in AI may be 
increasing or intermittent over time.24, 66 
No parameter that distinguished patients concerning change in cortisol production was 
identified. This is contrary to Morrelli et al. who found that worsening was associated to larger 
mass diameter at diagnosis.65 
Additionally, the absence of development of OCS, pheochromocytoma or PHA is 
compatible with recent studies,19, 40, 45, 48 except for Cho et al. that described de development of 
1 (0.7%) case of pheochromocytoma.47 
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SURGERY 
The proportion of patients submitted to surgery (2.1%) was lower than those described 
by other studies (6.1-47.7%).19, 20, 39-42, 47, 49, 52 This difference may be attributed to the stricter 
surgery criteria used in our institution. Among patients with indication for surgery, the 
proportion of each indication and the reasons for not undergoing surgery were similar to other 
studies.41, 47 Slight differences concerning the proportion of each indication may be attributed 
mainly to the absence of malignancy in our study and the fact that PACS or ACS were not 
considered an indication for surgery. 
NON-FUNCTIONING VERSUS POSSIBLE OR AUTONOMOUS CORTISOL SECRETION 
The literature concerning differences between patients with PACS or ACS and those with 
non-functioning AI is rather contradictory. Regarding age, some studies are in agreement with 
ours and described a greater age in patients with PACS or ACS;45, 65 contrarily, Tabuchi et al. 
described a younger age in these patients;49  and other studies reported no age differences.19, 40, 
47 Concerning sex, most recent studies are in agreement with ours and found no significant 
differences;19, 40, 45, 49, 65 only Cho et al. described a higher proportion of women in patients with 
PACS or ACS.47 Regarding imaging characteristics, some studies are in agreement with ours and 
found no differences concerning mass location,45, 47 while others described a higher proportion 
of bilateral masses in patients with PACS or ACS.6, 40, 52, 59, 60, 65 To our knowledge, only Cho et al. 
described differences regarding number of masses and, as in our study, no differences were 
found.47 Moreover, some studies are in agreement with ours and found no differences 
concerning diameter,19, 47 and others described a higher diameter in patients with PACS or ACS.6, 
40, 45, 49, 65 Additionally, and contrarily to our study which found no differences, some studies 
described a higher density in patients with PACS or ACS.40, 47 It is important to note that some 
of these studies are slightly different from ours as they included in the same group other 
functioning AIs besides PACS or ACS, although their proportions were very low.47, 49  
Furthermore, as already mentioned, several studies reported that cortisol excess in PACS 
or ACS is associated with an increased cardiovascular risk by inducing multiple metabolic 
derangements,9, 11, 12, 65, 67 that include overweight and obesity, prediabetes and DM,1, 45, 65 
hypertension1, 49 and dyslipidaemia.1, 19 On the contrary, our study found no differences between 
patients with PACS or ACS and those with non-functioning AI at diagnosis and 5 years after 
regarding the prevalence of comorbidities or cardiovascular events, which is partially or totally 
supported by some recent studies, that found only one difference or no differences between 
these groups of patients regarding these comorbidities.19, 40, 45, 47, 49 Additionally, in our study, no 
significant differences were found between patients with PACS or ACS and those with non-
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functioning AI concerning the development of comorbidities. Moreover, no differences were 
found regarding presence of comorbidities at diagnosis in patients who later developed 
comorbidities during follow-up and concerning time from diagnosis to development of these 
comorbidities. Nevertheless, patients with PACS or ACS appeared to have more cardiovascular 
events than those from the non-functioning group.  
There are at least three factors that may explain these contradictory results seen in 
literature. Firstly, it is important to keep in mind the heterogeneity among diagnostic criteria 
previously discussed. Secondly, it was hypothesized that non-functioning, PACS and ACS AI 
have a common origin and only represent distinct phases of the same phenomena, in other 
words, a continuum of cortisol production that may result in an increasing cardiovascular risk. 
In fact, several studies have found that non-functioning AI also have an increased risk of 
comorbidities (particularly insulin resistance and DM) and cardiovascular events and that this 
risk could be explained by secretion of low cortisol levels.24-26 This new perspective not only led 
to the questioning of the previously defined cortisol cut-offs that were used in studies but also 
to the realization of how heterogeneous study groups can be regarding cortisol production. For 
instance, a study might have a non-functioning group with a mean cortisol production 
significantly lower than other study with consequent impact on its outcomes. On the other hand, 
this increased cardiovascular risk of non-functioning AI may also bring back to discussion an 
older theory about the origin of AI that proposed ischemia (mainly in the context of 
atherosclerosis) as a triggering factor. This theory may also explain the increased risk in PACS 
and ACS group. Lastly, the possibility of intermittent production can influence studies’ 
outcomes, since this phenomenon may not be detected. 
Concerning the subanalysis to evaluate the performance of other diagnostic tests in 
comparison with 1 mg DST, we verified that although LNSC at diagnosis was significantly higher 
in PACS or ACS group, there were no significant differences concerning MSC and UFC. When 
analysing the agreement between 1 mg DST and LNSC at diagnosis, we obtained low Kappa 
coefficients using 1.8 μg/dL or 5.0 μg/dL as cut-offs. Moreover, it was not possible to analyse 
the agreement between 1 mg DST and UFC at diagnosis since there were no values of UFC 
above the upper limit of normal range. This is in agreement with Kastelan et al. that described 
that only 25% of the patients with ACS (defined as serum cortisol levels >3 µg/dL in 1 mg DST) 
had elevated UFC and with Di Dalmazi et al. that found no significant differences regarding UFC 
between patients with non-functioning AI, PACS and ACS.40, 45 These results concerning UFC 
may be explained by the low sensitivity of this method and by errors in the 24h-urine sampling. 
Those regarding LNSC may also be explained by sampling errors. In fact, although all sampling 
methods are explained in detail to the patients, they are complex and time-consuming. 
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Among the 93 patients who had at least 1 evaluation of MSC and LNSC at diagnosis, 14 
patients had inversion of the circadian rhythm on the first evaluation. Patients with PACS or ACS 
revealed a tendency to a higher proportion of inversion of the circadian rhythm (P=0.069), which 
is in agreement Debono et al.68 In fact, these results could also be influenced by sampling errors 
already discussed, particularly the exchange in the MSC and LNSC tubes that can easily occur. 
LIMITATIONS 
Our study presents some limitations: (1) the retrospective design; (2) the fact that it only 
included patients from a single centre (a tertiary care and university institution) which may 
constitute a selection bias; (3) the unavailability of some data; (4) the short median follow-up 
duration; (5) the size of the sample; (6) the fact that CTs were neither analysed by the same 
radiologists nor performed in the same equipment. 
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CONCLUSIONS 
In conclusion, our results suggest that most AIs remain stable during imaging follow-
up and that malignancy is a rare event. This is supported by other studies and justifies the 
current European guidelines recommendation of no further imaging evaluation after an 
unequivocally benign initial CT. 
Many studies have associated a higher risk of metabolic comorbidities and 
cardiovascular events not only in PACS or ACS but also in non-functioning AI, which suggests 
that globally patients with AI have a higher cardiovascular risk. This high risk is compatible with 
our results that also suggest that prevention may improve these patients’ outcomes. 
Nevertheless, more studies are needed to evaluate the importance of a clinical and biochemical 
follow-up oriented towards cardiovascular risk in patients with AI and in which context this 
follow-up should occur (primary, secondary or tertiary-care centres) so that current 
recommendations can be adjusted. 
According to our results and most recent studies, development of pheochromocytoma 
and PHA is a rare event. This supports the recommendation of current European guidelines to 
only evaluate RAA and urinary catecholamines and metanephrines at first visit and repeat merely 
if these initial results are abnormal. Regarding cortisol production, our study supports the 
contemporary view that this production may be increasing or intermittent over time. In this 
context, a single evaluation of cortisol production at diagnosis seems insufficient so that it is 
important to design studies in the future that can evaluate the relevance of monitoring cortisol 
secretion and which periodicity has the best cost-effectiveness ratio. Moreover, it is imperative 
to evaluate the role of UFC, LNSC and inversion of the circadian rhythm (with MSC and LNSC) 
in AIs’ study, since our results suggest they have a limited role. Additionally, the utility of 
dexamethasone dosing in the interpretation of 1 mg DST should be analysed. 
We hope that our study will function as a starting point for not only a larger Portuguese 
multicentre study which would allow a more accurate characterization of the epidemiology of 
AIs in Portugal but also a larger prospective study regarding AI’s follow-up and its associated 
long-life cardiovascular risk. 
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Table I: Demographic and imaging features at diagnosis. 
 n % 
Demographic features 
  Women 78  54.9 
Age, years   
  Mean (SD) 59.4  (12.1) 
  <40 5 3.5 
  40-69 107 75.4 
  >69 30 21.1 
Imaging features 
Imaging modality that led to diagnosis 
  Computed tomography scan 111 78.2 
  Ultrasonography 29 20.4 
  Magnetic resonance scan 2 1.4 
Indication for performing the diagnostic imaging study 
  Gastrointestinal symptoms or disease 71 50.0 
  Genitourinary symptoms or disease 22 15.5 
  Cardiopulmonary symptoms or disease 16 11.3 
  Others* 17 12.0 
  Unknown 16 11.3 
Mass location 
  Unilateral 118 83.1 
Left adrenal gland 63 53.4 
Right adrenal gland 55 46.6 
  Bilateral 24 16.9 
Number of masses 
  One 113 79.6 
  Two 21 14.8 
  Three 7 4.9 
  Four 1 0.7 
Maximum diameter, mm** 
  Mean (SD) 21.9 (12.0) 
  < 10 4 2.8 
  10-19 63 44.7 
  20-29 49 34.8 
  30-39 16 11.3 
  ≥ 40 9 6.4 
Non-contrast attenuation coefficient, Hounsfield units** 
  Described 115 81.6 ≤ 10 105 91.3 
> 10 10 8.7 
  Not described 26 18.4 
N=142. SD: standard deviation; *Other indications included trauma, 
anaemia, syncope, weight loss and abdominal aorta aneurysm; **Data 
concerning maximum diameter and non-contrast attenuation coefficient 
were not available for 1 patient because we did not have access to the 
full report or the images. 	
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Table II: First computed tomography scan features by diagnostic imaging modality. 
 CT or MR (n=113) 
US* 
(n=29) P-value 
 n % n %  
Mass location 0.004 
  Left adrenal gland 58 51.3 5 17.2  
  Right adrenal gland 39 34.5 16 55.2  
  Bilateral 16 14.2 8 27.6  
Number of masses 0.415 
  One 92 81.4 21 72.4  
  Two 14 12.4 7 24.1  
  Three 6 5.3 1 3.4  
  Four 1 0.9 0 0  
Maximum diameter, mm 0.115 
  Mean (SD) 20.9 (12.0) 25.7 (11.5) 0.019 
  < 10 4 3.5 0 0  
  10-19 55 48.7 8 28.6  
  20-29 37 32.7 12 42.9  
  30-39 12 10.6 4 14.3  
  ≥ 40 5 4.4 4 14.3  
CT: computed tomography scan; MR: magnetic resonance scan; SD: standard 
deviation; US: ultrasonography; *Data concerning maximum diameter was 
not available for 1 patient because we did not have access to the full report or 
the images. 
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Table III: Demographic features and comorbidities at diagnosis and 5 years after diagnosis. 
 At diagnosis (n=142) 
5 years after 
(n=62) 
 n  % n  % 
Comorbidities 
  Altered body mass index*  80 69.6 36 58.1 
Overweight 47 58.8 20 55.6 
Obesity 33 41.3 16 44.4 
  Dyslipidaemia 94 66.2 48 77.4 
Evaluated 69 73.4 26 54.2 
Controlled 12 17.4 8 30.8 
Hypercholesterolaemia 26 37.7 12 46.2 
Hypertriglyceridemia 9 13.0 2 7.7 
Hypocholesterolaemia HDL 7 10.1 2 7.7 
Combined 15 21.7 2 7.7 
Not evaluated 25 26.6 22 45.8 
  Hypertension 80 56.3 42 67.7 
Evaluated 64 80.0 31 73.8 
Controlled 29 45.3 11 35.5 
SBP 140-159 and/or DBP 90-99 26 40.6 15 48.4 
SBP 160-179 and/or DBP 100-109 8 12.5 5 16.1 
SBP ≥ 180 and/or DBP ≥ 110 1 1.6 0 0 
Not evaluated 16 20.0 11 26.2 
  Tobacco smoking habits 49 34.5 17 27.4 
Former smoker 10 20.4 2 11.8 
Current smoker 39 79.6 15 88.2 
  Glucose intolerance 47 33.1 26 41.9 
Prediabetes 14 29.8 14 53.8 
Diabetes 33 70.2 12 46.2 
  History of cardiovascular events 14 9.9 4 6.5 
Coronary heart disease 7 50.0 3 75.0 
Cerebrovascular disease 2 14.3 1 25.0 
Peripheral artery disease 2 14.3 0 0 
Multiple territories 3 21.4 0 0 
DBP: diastolic blood pressure; HDL: high-density lipoprotein; SBP: systolic blood 
pressure; *27 missing at diagnosis and 15 missing 5 years after diagnosis. 
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Table IV: Clinical and biochemical features at diagnosis and 5 years after diagnosis. 
 At diagnosis 
(n=142) 
5 years after  
(n=62) 
   n Mean SD n Mean SD 
Clinical evaluation 
  Body mass index (kg/m2) 115 28.0 4.9 47 28.1 4.2 
  Waist circumference (cm) 59 101.7 12.0 2 104.0 4.2 
  Systolic blood pressure (mmHg) 114 134.9 17.6 47 136.2 15.8 
  Diastolic blood pressure (mmHg) 114 78.6 10.7 47 77.4 10.2 
General biochemical evaluation 
  Fasting glucose (mg/dL) 115 104.5 27.4 41 98.9 29.6 
  Total cholesterol (mg/dL) 92 189.0 44.2 29 193.6 30.2 
  LDL cholesterol (mg/dL) 83 114.1 39.0 27 115.5 28.3 
  HDL cholesterol (mg/dL) 87 52.6 14.3 27 58.7 15.6 
  Triglycerides (mg/dL) 93 119.5 77.0 29 107.7 42.9 
  Homeostasis model assessment index* 32 3.3 (2.6-6.9) 5 3.1 (1.9-4.9) 
  Triglyceride/glucose index 93 8.5 0.6 29 8.5 0.5 
Hormonal evaluation 
  1 mg DST (µg/dL) 50 1.9 1.6 17 2.5 1.4 
  24-h urinary free cortisol (µg/24h) 85 47.2 33.7 22 44.7 32.3 
  Morning salivary cortisol (µg/dL) 57 0.515 0.319 7 0.530 0.287 
  Late night salivary cortisol (µg/dL)  54 0.214 0.280 8 0.208 0.145 
  Plasma aldosterone/renin ratio 80 24.5 44.5 11 36.7 41.3 
  Plasma metanephrine (pmol/L) 2 420.1 325.4 8 198.0 58.7 
  Plasma normetanephrine (pmol/L) 2 1081.3 264.0 8 447.5 206.5 
  24-h urinary adrenaline (nmol/24h) 86 27.9 28.5 22 35.4 33.7 
  24-h urinary noradrenaline (nmol/24h) 92 244.8 128.8 23 274.1 163.1 
  24-h urinary dopamine (nmol/24h) 92 1245.0 659.5 23 1162.6 618.7 
  24-h urinary metanephrine (nmol/24h) 90 470.7 271.0 23 451.7 344.4 
  24-h urinary normetanephrine (nmol/24h) 90 1506.6 646.1 23 1665.0 947.7 
1 mg DST: overnight low-dose dexamethasone suppression test; HDL: high-density lipoprotein; LDL: low-
density lipoprotein; SD: standard deviation; *Median, Interquartile range. 
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Table V: Demographic, clinical and analytical features at diagnosis and 5 years after diagnosis 
grouped by cortisol production. 
 
Non-functioning AI* PACS or ACS** P-value 
Demographic features N n % N n %  
  Women 
At diagnosis  65 38 58.5 37 20 54.1 0.666 
5 years after 34 23 67.6 18 10 55.6 0.389 
  Mean age (SD), years 
At diagnosis 65 57.2 (11.9) 37 63.4 (13.0) 0.006 
5 years after 34 60.2 (11.0) 18 68.3 (13.0) 0.006 
Comorbidities N n % N n %  
  Dyslipidaemia 
At diagnosis 65 46 70.8 37 26 70.3 0.958 
5 years after 34 29 85.3 18 16 88.9 1.000 
  Glucose intolerance 
At diagnosis 65 18 27.7 37 16 43.2 0.156 
5 years after 34 14 41.2 18 9 50.0 0.542 
Prediabetes 
At diagnosis  8 44.4  3 18.8  
5 years after  8 57.1  5 55.6  
Diabetes 
At diagnosis  10 55.6  13 81.3  
5 years after  6 42.9  4 44.4  
  Hypertension 
At diagnosis 65 32 49.2 37 24 64.9 0.127 
5 years after 34 20 58.5 18 14 77.8 0.172 
  Altered body mass index  
At diagnosis 38 37 56.9 37 21 56.8 0.987 
5 years after 32 25 73.5 18 10 55.6 0.189 
Overweight 
At diagnosis  23 62.2  12 57.1  
5 years after  14 56.0  6 60.0  
Obesity 
At diagnosis  14 37.8  9 42.9  
5 years after   11 44.0  4 40.0  
  Cardiovascular events 
At diagnosis 65 3 4.6 37 3 11.3 0.665 
5 years after 34 1 5.6 18 2 11.1 0.272 
Clinical evaluation  N Mean SD N Mean SD  
  Body mass index, kg/m2 
At diagnosis  54 27.9 4.5 29 27.8 5.0 0.849 
5 years after 33 28.1 3.8 12 28.3 4.6 0.904 
  Waist circumference, cm  
At diagnosis 23 99.6 11.6 12 102.7 8.8 0.430 
5 years after 2 104.0 4.2 0    
  Systolic blood pressure, mmHg 
At diagnosis 54 134.7 18.3 29 135.9 17.7 0.454 
5 years after 33 136.5 20.8 12 135.0 20.8 0.690 
  Diastolic blood pressure, 
mmHg  
At diagnosis 54 78.6 11.8 29 76.3 8.9 0.362 
5 years after 33 77.5 11.2 12 75.9 7.3 0.961 
General biochemical evaluation N Mean SD N Mean SD  
  Fasting glucose, mg/dL  
At diagnosis 55 101.1 26.0 29 108.2 26.1 0.081 
5 years after 28 94.1 24.5 11 112.7 40.1 0.297 
  Total cholesterol, mg/dL 
At diagnosis 47 195.4 42.7 22 180.1 38.7 0.986 
5 years after 19 199.8 29.4 9 183.8 30.7 0.212 
  LDL cholesterol, mg/dL 
At diagnosis 42 118.2 37.6 20 107.8 27.9 0.745 
5 years after 18 117.8 30.0 9 110.8 25.4 0.482 
  HDL cholesterol, mg/dL 
At diagnosis 44 53.0 14.0 22 52.0 10.4 0.353 
5 years after 18 61.6 16.2 9 53.0 13.3 0.089 
  Triglycerides, mg/dL  At diagnosis 47 117.7 75.1 22 129.8 101.1 0.912 
  34 
5 years after 19 108.6 49.6 9 105.9 30.0 0.565 
  Homeostasis model 
assessment index*** 
At diagnosis 17 4.2 (2.8-7.8) 9 4.3 (2.7-5.7) 0.641 
5 years after 5 3.1 (1.8-4.9) 0    
  Triglyceride/glucose index 
At diagnosis 47 8.5 0.6 22 8.6 0.6 0.465 
5 years after 19 8.4 0.6 9 8.5 0.4 0.415 
Cortisol evaluation  N Mean SD N Mean SD  
  1 mg DST, µg/dL 
At diagnosis 28 1.1 0.4 15 3.2 1.8 <0.001 
5 years after 10 1.6 0.4 7 3.8 1.3 0.001 
  24-h urinary free cortisol, 
µg/24h 
At diagnosis 47 47.9 39.4 21 43.8 27.9 0.545 
5 years after 17 43.0 25.2 4 51.2 61.9 0.869 
  Morning salivary cortisol, 
µg/dL 
At diagnosis 30 0.499 0.192 13 0.611 0.366 0.139 
5 years after 5 0.516 0.349 2 0.566 0.054 0.699 
  Late night salivary cortisol, 
µg/dL 
At diagnosis 29 0.118 0.103 12 0.446 0.431 0.005 
5 years after 5 0.227 0.165 3 0.176 0.130 0.764 
1 mg DST: overnight low-dose dexamethasone suppression test; AI: adrenal incidentaloma; ACS: autonomous cortisol 
secretion; HDL: high-density lipoprotein; LDL: low-density lipoprotein; PACS: possible autonomous cortisol secretion; SD: 
standard deviation; *n=65 at diagnosis and 34 five years after; **n=37 at diagnosis and 18 five years after; ***Median 
(Interquartile range). 
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Table VI: Computed tomography scan features at diagnosis grouped by cortisol production. 
 
Non-functioning 
AI 
(n=65)* 
PACS or ACS 
(n=37) P-value 
 n % n %  
Mass location 0.976 
  Left adrenal gland 29 44.6 17 45.9  
  Right adrenal gland 26 40.0 14 37.8  
  Bilateral 10 15.4 6 16.2  
Number of masses 0.556 
  One 52 80.0 29 78.4  
  Two 11 16.9 5 13.5  
  Three 2 3.1 2 5.4  
  Four 0 0 1 2.7  
Maximum diameter, mm 0.371 
  Mean (SD) 21.0 (10.3) 24.1 (11.4) 0.145 
  < 10 1 1.6 1 2.7  
  10-19 31 48.4 14 37.8  
  20-29 23 35.9 11 29.7  
  30-39 6 9.4 7 18.9  
  ≥ 40 3 4.7 4 10.8  
Non-contrast attenuation coefficient, Hounsfield units** 0.085 		≤ 10 47 88.7 29 100  
  > 10 6 11.3 0 0  
AI: adrenal incidentaloma; ACS: autonomous cortisol secretion; PACS: possible 
autonomous cortisol secretion; SD: standard deviation; *Data concerning 
maximum diameter and mass density was not available for 1 patient because we 
did not have access to the full report or the exam; **For 20 subjects (12 with non-
functioning AI and 8 with PACS or ACS) the radiologist did not report non-contrast 
attenuation coefficient and we could not access to the diagnostic exam. 
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FIGURES 
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PHA: Primary hyperaldosteronism; PHEO: pheochromocytoma; ↓: decrease. 
Figure 1: Flow-diagram of patients’ inclusion, patients with indication for surgery at diagnosis and during follow-up and patients who underwent surgery.  
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n (%); *Other specializations included infectiology (3 patients), nephrology (3), endocrinology (2), haematology (1), neurology (1) and physical medicine and rehabilitation (1). 
Figure 2: Specialties of the physicians who referred the patients.  
  
0% 10% 20% 30% 40% 50%
Others*
Cardiology
Urology
General surgery
Internal medicine
Gastroenterology
Family medicine 62 (43.7%)
31 (21.8%)
18 (12.7%)
11 (7.7%)
5 (3.5%)
4 (2.8%)
11 
  39 
 
On the right side of the figure, numbers concerning patients with possible autonomous cortisol secretion or autonomous cortisol secretion are inside yellow squares and those 
concerning patients with non-functioning adrenal incidentalomas are inside orange ones. PHA: Primary hyperaldosteronism. 
Figure 3: Diagram with patients who developed comorbidities throughout follow-up in global and grouped by cortisol production. 
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ACS: Autonomous cortisol secretion; PACS: Possible autonomous cortisol secretion; PHA: Primary hyperaldosteronism; PHEO: pheochromocytoma; NF: Non-functioning; 
*One also had PACS and another ACS; **Also had PACS; ***One also had PACS and the other ACS. 
Figure 4: Diagram with the classification of patients according to hormone production at diagnosis and at the end of follow-up and with the change in 
cortisol production throughout follow-up. 
